Abstract
The invention relates generally to novel EPAC1 activators, such as Formula (I) and (II) and the preparation thereof as well as the use of EPAC1 activators disclosed herein as to selectively activate EPAC1 in cells.
Original language | English |
---|---|
Patent number | US2021022839W |
IPC | C07C311/16, C07C311/17,C07C311/20 |
Priority date | 17/03/20 |
Filing date | 17/03/21 |
Publication status | Published - 23 Sept 2021 |